|
Market Closed -
Nasdaq
06:00:00 14/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 516.44 USD | -1.77% |
|
+6.70% | +13.91% |
| 13/08 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 11/08 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 563.12 | +7.11% | 25 | ||||||
| 1,299.56 | +6.5% | 27 | ||||||
| 272.5 | +4.46% | 22 | ||||||
| 275.39 | +10.71% | 28 | ||||||
| 370.31 | +1.31% | 18 | ||||||
| 154.19 | +0.78% | 21 | ||||||
| 211.65 | +33.92% | 22 | ||||||
| 381.59 | -8.31% | 29 | ||||||
| 313.54 | +4.69% | 24 | ||||||
| 157.41 | +15.85% | 27 | ||||||
| 28.64 | +8.87% | 26 | ||||||
| 66.21 | +3.94% | 24 | ||||||
| 94.28 | +25% | 23 | ||||||
| 21.61 | +15.64% | 20 | ||||||
| 9,513.33 | +32.42% | 15 | ||||||
| 6,387.69 | +14.85% | 16 | ||||||
| 56.81 | +18.34% | 18 | ||||||
| 79.69 | +46.59% | 16 | ||||||
| 4.208 | +16.93% | 17 | ||||||
| 41.4 | +12.68% | 10 | ||||||
| Average | 1,014.66 | +13.61% | 21 | ||||||
| Weighted average by Cap. | 712.52 | +8.79% | 24 |
- Stock Market
- Stocks
- VRTX Stock
- Sector Vertex Pharmaceuticals Incorporated
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
